Jason Sutin

Jason Sutin

Auto-generated profile, based on publicly available information

Jason Sutin

Boston Children's Hospital

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in NeuroImage
Verified
Journal Article
Closed access
LVLana Vasung
Lana Vasung
ETEsra Abaci Turk
Esra Abaci Turk
SFSilvina L. Ferradal
Silvina L. Ferradal
JSJason Sutin
Jason Sutin
JSJeffrey N. Stout
Jeffrey N. Stout
PGPatricia Ellen Grant
Patricia Ellen Grant

13 November 2018 in Neurophotonics
Verified
Journal Article
Closed access
PDF file
JSJuliette Selb
Juliette Selb
KWKuan-Cheng Wu
Kuan-Cheng Wu
JSJason Sutin
Jason Sutin
Pei-Yi LinPei-Yi Lin
Pei-Yi Lin
PFParisa Farzam
Parisa Farzam
EREric S. Rosenthal
Eric S. Rosenthal
Monitoring of cerebral blood flow (CBF) and autoregulation are essential components of neurocritical care, but continuous noninvasive methods for CBF monitoring are lacking. Diffuse correlation spectroscopy (DCS) is a noninvasive diffuse optical modality that measures a CBF index (CBFi) in the cortex microvasculature by monitoring the rapid fluctuations of near-infrared light diffusing through moving red blood cells. We tested the feasibility of monitoring CBFi with DCS in at-risk patients in the Neurosciences Intensive Care Unit. DCS data were acquired continuously for up to 20 h in six patients with aneurysmal subarachnoid hemorrhage, as permitted by clinical care. Mean arterial blood pressure was recorded synchronously, allowing us to derive autoregulation curves and to compute an autoregulation index. The autoregulation curves suggest disrupted cerebral autoregulation in most patients, with the severity of disruption and the limits of preserved autoregulation varying between subjects. Our findings suggest the potential of the DCS modality for noninvasive, long-term monitoring of cerebral perfusion, and autoregulation.

29 June 2023 in EBioMedicine
Verified
Journal Article
Open access
JSJason Sutin
Jason Sutin
RVRutvi Vyas
Rutvi Vyas
HFHenry A. Feldman
Henry A. Feldman
SFSilvina Ferradal
Silvina Ferradal
CHChuan-Heng Hsiao
Chuan-Heng Hsiao
PGPatricia Ellen Grant
Patricia Ellen Grant
Therapeutic hypothermia (TH) is standard of care for moderate to severe neonatal hypoxic ischemic encephalopathy (HIE) but many survivors still suffer lifelong disabilities and benefits of TH for mild HIE are under active debate. Development of objective diagnostics, with sensitivity to mild HIE, are needed to select, guide, and assess response to treatment. The objective of this study was to determine if cerebral oxygen metabolism (CMRO2) in the days after TH is associated with 18-month neurodevelopmental outcomes as the first step in evaluating CMRO2's potential as a diagnostic for HIE. Secondary objectives were to compare associations with clinical exams and characterise the relationship between CMRO2 and temperature during TH. This was a prospective, multicentre, observational, cohort study of neonates clinically diagnosed with HIE and treated with TH recruited from the tertiary neonatal intensive care units (NICUs) of Boston Children's Hospital, Brigham and Women's Hospital, and Beth Israel Deaconess Medical Center between December 2015 and October 2019 with follow-up to 18 months. In total, 329 neonates ≥34 weeks gestational age admitted with perinatal asphyxia and suspected HIE were identified. 179 were approached, 103 enrolled, 73 received TH, and 64 were included. CMRO2 was measured at the NICU bedside by frequency-domain near-infrared and diffuse correlation spectroscopies (FDNIRS-DCS) during the late phases of hypothermia (C), rewarming (RW) and after return to normothermia (NT). Additional variables were body temperature and clinical neonatal encephalopathy (NE) scores, as well as findings from magnetic resonance imaging (MRI) and spectroscopy (MRS). Primary outcome was the Bayley Scales of Infant and Toddler Development, Third Edition (BSID-III) at 18 months, normed (SD) to 100 (15). Data quality for 58 neonates was sufficient for analysis. CMRO2 changed by 14.4% per °C (95% CI, 14.2-14.6) relative to its baseline at NT while cerebral tissue oxygen extraction fraction (cFTOE) changed by only 2.2% per °C (95% CI, 2.1-2.4) for net changes from C to NT of 91% and 8%, respectively. Follow-up data for 2 were incomplete, 33 declined and 1 died, leaving 22 participants (mean [SD] postnatal age, 19.1 [1.2] month; 11 female) with mild to moderate HIE (median [IQR] NE score, 4 [3-6]) and 21 (95%) with BSID-III scores >85 at 18 months. CMRO2 at NT was positively associated with cognitive and motor composite scores (β (SE) = 4.49 (1.55) and 2.77 (1.00) BSID-III points per 10-10 moL/dl × mm2/s, P = 0.009 and P = 0.01 respectively; linear regression); none of the other measures were associated with the neurodevelopmental outcomes. Point of care measures of CMRO2 in the NICU during C and RW showed dramatic changes and potential to assess individual response to TH. CMRO2 following TH outperformed conventional clinical evaluations (NE score, cFTOE, and MRI/MRS) at predicting cognitive and motor outcomes at 18 months for mild to moderate HIE, providing a promising objective, physiologically-based diagnostic for HIE. This clinical study was funded by an NIH grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, United States (R01HD076258).

1 December 2005 in Review of Scientific Instruments
Verified
Journal Article
Closed access
PDF file
ZMZigurts K. Majumdar
Zigurts K. Majumdar
JSJason D. B. Sutin
Jason D. B. Sutin
RCRobert M. Clegg
Robert M. Clegg
We present a microfabricated, continuous-flow, turbulent mixing device that can mix two or more fluids to complete homogeneity on the molecular scale in the microsecond range. The current design is compact, portable, relatively simple to fabricate, adaptable for various measurement techniques, and consumes small sample volumes. The entire mixing process is observable and we use this feature to characterize the dependence of the progress of mixing on the flow velocity. We present details of the mixer’s construction and optical data acquisition using fluorescence. Because the mixer is constructed using microfabrication technology, it is inexpensive and alterations are easy to explore. We show that the dependence of mixing times and pressure drop on the flow velocity agree well with theoretical expectations for turbulent pipe flow. This provides useful guidelines in predicting performance of this type of mixing device.

14 January 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
TVTaylor Vadset
Taylor Vadset
ARAjay Rajaram
Ajay Rajaram
CHChuan-Heng Hsiao
Chuan-Heng Hsiao
MKMIRIAH KEMIGISHA
MIRIAH KEMIGISHA
Joshua Jayz MagombeJoshua Jayz Magombe
Joshua Jayz Magombe
Pei-Yi LinPei-Yi Lin
Pei-Yi Lin
Infant hydrocephalus poses a severe global health burden; 80% of cases occur in the developing world where patients have limited access to neurosurgical care. Surgical treatment combining endoscopic third ventriculostomy and choroid plexus cauterization (ETV/CPC), first practiced at CURE Children’s Hospital of Uganda (CCHU), is as effective as standard ventriculoperitoneal shunt (VPS) placement while requiring fewer resources and less post-operative care. Although treatment focuses on controlling ventricle size, this has little association with treatment failure or long-term outcome. This study aims to monitor the progression of hydrocephalus and treatment response, and investigate the association between cerebral physiology, brain growth, and neurodevelopmental outcomes following surgery. We will enroll 300 infants admitted to CCHU for treatment. All patients will receive pre/post-operative measurements of cerebral tissue oxygenation (SO2), cerebral blood flow (CBF), and cerebral metabolic rate of oxygen consumption (CMRO2) using frequency-domain near-infrared combined with diffuse correlation spectroscopies (FDNIRS-DCS). Infants will also receive brain imaging, to monitor tissue/ventricle volume, and neurodevelopmental assessments until two years of age. This study will provide a foundation for implementing cerebral physiological monitoring to establish evidence-based guidelines for hydrocephalus treatment. This paper outlines the protocol, clinical workflow, data management, and analysis plan of this international, multi-center trial.

20 February 2020 in Neurophotonics
Verified
Journal Article
Open access
PDF file
JSJuliette Selb
Juliette Selb
KWKuan-Cheng Wu
Kuan-Cheng Wu
JSJason Sutin
Jason Sutin
Pei-Yi LinPei-Yi Lin
Pei-Yi Lin
PFParisa Farzam
Parisa Farzam
EREric S. Rosenthal
Eric S. Rosenthal
<!-- *** Custom HTML *** --> Corrected disclosures for the article “Prolonged monitoring of cerebral blood flow and autoregulation with diffuse correlation spectroscopy in neurocritical care patients.” This article [Neurophotonics 5, 045005 (2018) doi: 10.1117/1.NPh.5.4.045005] was originally published online on 13 November 2018 with an error in the Disclosures section, where information regarding potential conflicts of interest was reported incompletely. Original: The authors hold patents on the DCS technology. MAF has a financial interest in 149 Medical, Inc., a company developing DCS technology for assessing and monitoring cerebral blood flow in newborn infants. MAF’s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. Corrected: MAF and DAB have financial interest in 149 Medical, Inc., a company developing DCS technology for assessing and monitoring cerebral blood flow in newborn infants, and in Dynometrics, Inc., a company that makes devices that use NIRS technology for athletes to evaluate muscle performance. MAF and DAB interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. This article was corrected online on 11 February 2020.